Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPOCx-iRex Trial: Hypofractionated Radiotherapy and iRex-Optimized Brachytherapy in Cervical Cancer
NCT07605507Active, not recruiting
- Sponsor
- Siriraj Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in Cervical Cancer (CC) (4 arms), sponsored by Siriraj Hospital. Primary endpoints: Incidence of Acute Treatment-Related Toxicity at 3 months and Incidence of Late (Chronic) Treatment-Related Toxicity at 5 years. Started Jul 2021; status: active, not recruiting.
02
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07605507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605507.